SONNET BIOTHERAPEUTICS HOLDINGS, INC.

Analyst Reco. Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Delayed Nasdaq Other stock markets 15:18:48 2024-05-17 EDT			5-day change	1st Jan Change
1.82 ^USD	-1.62%		+7.06%	+4.60%

03-11	Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	MT
03-11	Top Premarket Gainers	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating	02-15	MT
Ladenburg Thalmann Starts Sonnet BioTherapeutics Holdings With Buy Rating, $7 Price Target	11-27	MT
EF Hutton Assumes Sonnet BioTherapeutics at Buy With $6.70 Price Target	23-08-23	MT
Chardan Cuts Price Target on Sonnet BioTherapeutics to $12 From $14, Keeps Buy Rating	23-08-16	MT
EF Hutton Assumes Buy Rating on Sonnet BioTherapeutics With $6.70 Price Target	23-05-25	MT
Chardan Lowers Price Target on Sonnet BioTherapeutics to $14 From $17, Keeps Buy Rating	23-05-11	MT
Chardan Cuts Price Target on Sonnet BioTherapeutics to $17 From $22, Anticipating Higher Future Share Count, Maintains Buy Rating	23-04-19	MT
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	23-01-09	DJ
EF Hutton Initiates Coverage on Sonnet BioTherapeutics Holdings at Buy With $6.70 Price Target	22-12-19	MT
Chardan Adjusts Sonnet BioTherapeutics Holdings Price Target to $22 From $2, Maintains Buy Rating	22-09-22	MT
Chardan Trims Sonnet BioTherapeutics Holdings' Price Target to $2 From $2.50, Maintains Buy Rating	22-08-16	MT
Wall Street Set for Gains Ahead of Fed's Rate Decision	22-03-16	MT
BTIG Adjusts Price Target on Sonnet BioTherapeutics Holdings to $2 From $5, Reiterates Buy Rating	22-02-09	MT
Chardan Capital Adjusts Sonnet BioTherapeutics Holdings PT to $2.50 From $8, Maintains Buy Rating	21-12-20	MT
HC Wainwright Initiates Coverage on Sonnet BioTherapeutics Holdings With Buy Rating, $2 Price Target	21-12-16	MT
SONNET BIOTHERAPEUTICS : BTIG Starts Sonnet BioTherapeutics Holdings at Buy with $5 Price Target	21-09-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
SONN Stock
News Sonnet BioTherapeutics Holdings, Inc.
Analyst Reco.

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW